Aug. 15 at 5:14 PM
$RNXT technical + fundamental bull path:
The chart is testing the ~
$1.45 prior high after Q2 volume expansion. A sustained break/hold above it would confirm a new price regime. Next real supply sits around the
$1.75–
$1.93 milestone-warrant zone; absorbing that opens a credible path to
$2.
Fundamentals now support the setup: Q2 revenue
$909K (+61% QoQ), ~84% gross margin, 21 active centers +42 in the funnel, and TIGeR-PaC fully enrolled with 78/86 OS events.
$CRVS and
$PMVP investors know oncology reratings become nonlinear as catalysts compress.
My ladder: $ 2 = Q3 commercial confirmation + technical breakout. $ 4 = sustained 2026/27 scaling + trial completion/pre-readout repricing. $ 7 = bull case requiring clearly positive Phase III OS + credible regulatory path/platform expansion.
Not guaranteed—each level needs stronger evidence. But RNXT is no longer trading on the sub-$ 1 information set.
